Use of a non-laboratory virus strain, methods for determining whether a gene has an effect on a phenotype associated with a peripheral and central nervous system disorder or on a peripheral and central nervous system cell to determine whether a gene encodes an antigen associated with a pathogenic infection or cancer, to determine the suitability of a non-laboratory virus strain for modification to a modified strain, to determine whether a gene enhances the anti-tumor effects of a virus, and to produce an oncolytic non-laboratory virus strain. , modified, non-laboratory virus strain, use of a gene, hsv1 js1 strain, pharmaceutical composition, and, methods for treating a tumor in an individual, supplying a gene to an individual and treating or preventing a disorder of the peripheral nervous systems and central

摘要

"USE OF A NON-LABORATORY VIRUS CUP METHOD FOR DETERMINING IF A GENE HAS AN EFFECT ON A PHENOTYPLE ASSOCIATED WITH A PERIPHERAL AND CENTRAL NERVOUS SYSTEMS FOR A CELL OF THE NUMEROUS PERIPHERAL CINEMARIAN SYSTEMS ASSOCIATED WITH A PATHOGENIC INFECTION OR CANCER TO DETERMINE THE SUITABILITY OF A NON-LABORATORY VIRUS CUP FOR MODIFICATION TO A MODIFIED CUP TO DETERMINE IF A GENE INCREASES ANTI-TUMOR EFFECTS OF A VIRAL VIRAL NURPLE , MODIFIED, NON-LABORATORY VIRUS CUP, USE OF A GENE, CEPA HSV1 JS1, PHARMACEUTICAL COMPOSITION, AND, METHODS TO TREAT A TUMOR IN AN INDIVIDUAL AND TO TREAT A DIFFERENT OR IMPIRES DURING THE PERSPECTIVE AND CENTRAL ". The present invention relates to non-laboratory virus strains, for example of herpes viruses, such as HSV, with improved oncolytic and / or genetic supply capabilities compared to laboratory virus strains.